The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
 
Saad Zafar Usmani
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Merck; Oncopeptides; Seagen; Skyline Diagnostics; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Sanofi; Takeda
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Pharmacyclics; Sanofi; Seagen; Skyline Diagnostics
 
Thomas G. Martin
Consulting or Advisory Role - GlaxoSmithKline; Juno Therapeutics
Research Funding - AMGEN (Inst); Janssen Oncology (Inst); Sanofi (Inst)
 
Jesus G. Berdeja
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Legend Biotech (Inst); Secura Bio (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celularity (Inst); crispr therapeutics (Inst); EMD Serono (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ichnos Sciences (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst)
 
Andrzej J. Jakubowiak
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
 
Mounzer E. Agha
No Relationships to Disclose
 
Adam D. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol Meyers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Novartis; Oncopeptides; Roche/Genentech; Seagen; Takeda
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome
Expert Testimony - Janssen Oncology
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Takeda
 
Abhinav Deol
Consulting or Advisory Role - Adicet Bio; Agios; Janssen; Juno/Celgene; Kite/Gilead; Novartis
 
Myo Htut
Consulting or Advisory Role - Millennium
Research Funding - BMS (Inst); Judy and Bernard Briskin Center for Multiple Myeloma Research (Inst)
Travel, Accommodations, Expenses - Millennium
 
Alexander M. Lesokhin
Honoraria - ITeos Therapeutics; Janssen; Legend Biotech; Pfizer; Sanofi; Trillium Therapeutics
Consulting or Advisory Role - Pfizer; Trillium Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Serametrix, Inc
 
Nikhil C. Munshi
Stock and Other Ownership Interests - C4 Therapeutics; OncoPep; Raqia
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Janssen; Karyopharm Therapeutics; Legend Biotech; Novartis; OncoPep; Raqia; Sebia; Takeda
Patents, Royalties, Other Intellectual Property - Oncopep
 
Elizabeth O'Donnell
Consulting or Advisory Role - Adaptive Biotechnologies; Bristol-Myers Squibb; Karyopharm Therapeutics; Oncopeptides; Takeda
 
Carolyn Chang Jackson
Employment - Janssen Research & Development
Consulting or Advisory Role - Memorial Sloan-Kettering Cancer Center
 
Tzu-min Yeh
Employment - Janssen Research & Development
 
Arnob Banerjee
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Enrique Zudaire
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Patents, Royalties, Other Intellectual Property - Patents pending with Janssen
Travel, Accommodations, Expenses - Janssen Research & Development
 
Deepu Madduri
Employment - Janssen Oncology
Stock and Other Ownership Interests - Roivant (I); Sio Gene Therapies (I)
Consulting or Advisory Role - Celgene; Foundation Medicine; GlaxoSmithKline; Janssen Oncology; Legend Biotech; Takeda
 
Changwei Zhou
Employment - Legend Biotech
 
Lida Bubuteishvili-Pacaud
Employment - Legend biotech
Stock and Other Ownership Interests - Legend Biotech
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Sundar Jagannath
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Legend Biotech; Sanofi; Takeda
Travel, Accommodations, Expenses - Brystol-Myers Squibb; Janssen Biotech